Cefotaxime breakpoint for Streptococcus pneumoniae

Cantón, Emilia

doi:10.1128/aac.37.3.616

Cited by 23 publications

(8 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Few authors have described clinical pneumococcal isolates with a high level of resistance to thirdgeneration cephalosporins [11,18,21]. Moreover, CFTR pneumococci have been associated with failed CTX therapy [19,33]. These CFTR strains appeared unusual relative to other P' isolates with regard to several properties [l 11.…”

Section: Discussionmentioning

confidence: 99%

In vivo efficacy of cefotaxime and amoxicillin against penicillin-susceptible, penicillin-resistant and penicillin-cephalosporin-resistant strains of Streptococcus pneumoniae in a mouse pneumonia model

Moine

Sauve

Vallée

et al. 1997

Clinical Microbiology and Infection

View full text Add to dashboard Cite

OBJECTIVE: To compare cefotaxime (CTX) to amoxicillin (AMO) (usually considered the definitive therapy for penicillin-susceptible Streptococcus pneumoniae infections) in an immunocompromised mouse pneumonia model. METHODS: Three S. pneumoniae clinical isolates were used: two serotype 19 strains, a penicillin-susceptible (Ps) strain (penicillin MIC=0.03 microg/mL) and a highly penicillin-resistant (Pr) strain (penicillin MIC=4 microg/mL), and one serotype 23F strain, a penicillin---cephalosporin-resistant (CFTR) strain (CTX MIC=4 microg/mL). RESULTS: CTX activity in this mouse model of pneumonia induced by the highly penicillin-resistant strain of S. pneumoniae was lower than expected from its low MIC against this organism. Furthermore, AMO had greater efficacy than CTX against a CFTR S. pneumoniae strain. CONCLUSION: Our data suggest that there is no major difference in the in vivo efficacy of the two agents, cefotaxime and amoxicillin, against penicillin-resistant and penicillin---cephalosporin-resistant S. pneumoniae.

show abstract

Section: Discussionmentioning

confidence: 99%

In vivo efficacy of cefotaxime and amoxicillin against penicillin-susceptible, penicillin-resistant and penicillin-cephalosporin-resistant strains of Streptococcus pneumoniae in a mouse pneumonia model

Moine

Sauve

Vallée

et al. 1997

Clinical Microbiology and Infection

View full text Add to dashboard Cite

show abstract

“…The lack of a standard criterion of resistance to erythromycin in S. pneumoniae makes it difficult to compare trends in resistance. Other investigators (1,16,17) recently called attention to the need for the NCCLS to develop criteria specifically for susceptibility testing of S. pneumoniae.…”

Section: Discussionmentioning

confidence: 99%

High rate of erythromycin and clarithromycin resistance among Streptococcus pneumoniae isolates from blood cultures from Providence, R.I

Lonks

Medeiros

1993

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Four (5%) of 81 recent isolates of Streptococcus pneumoniae from the blood of adult patients but no isolates from pediatric patients (n = 51) were resistant (MIC, 21 ,g/ml) to erythromycin. The MICs of clarithromycin were slightly lower than those of erythromycin, but there was complete cross-resistance. Routine testing and surveillance are needed to determine whether erythromycin resistance among S. pneumoniae isolates is increasing throughout the United States.

show abstract

“…This has led to therapeutic failures in patients with meningitis and to the use of broad-spectrum cephalosporins in this setting (15,26). Cases of meningitis caused by S. pneumoniae strains resistant to broad-spectrum cephalosporins have recently been reported, together with therapeutic failures and delayed sterilization of cerebrospinal fluid (CSF) when these drugs were used (5,6,13,16,22). Imipenem has an excellent in vitro activity against penicillin-resistant pneumococci, but its value in patients with meningitis is limited because of its seizure activity (8).…”

mentioning

confidence: 99%

Killing activity of cefpirome against penicillin-resistant Streptococcus pneumoniae isolates from patients with meningitis in a pharmacodynamic model simulating the cerebrospinal fluid concentration profile

Fitoussi

Sandin

Péchinot

et al. 1995

Antimicrob Agents Chemother

View full text Add to dashboard Cite

An in vitro pharmacodynamic model was used to determine the killing kinetics of cefpirome against 20 Streptococcus pneumoniae strains (penicillin G MICs, >0.125 to 2 g/ml) isolated from patients with meningitis. The concentration of cefpirome was adjusted dynamically to simulate the median concentration profile obtained in the cerebrospinal fluid of adults after the infusion of a single dose of 2 g. The cefpirome MIC at which 90% of isolates are inhibited was 0.5 g/ml. Bactericidal activity was observed at 6 h, with mean killing of 3.51 ؎ 0.34 log 10 CFU/ml for all strains for which the cefpirome MIC was <0.5 g/ml. In contrast, for strains for which the cefpirome MIC was >0.5 g/ml, killing was significantly less (P < 0.05), with a mean reduction of only 2.86 ؎ 0.57 log 10 CFU/ml.

show abstract

Cefotaxime breakpoint for Streptococcus pneumoniae

Cited by 23 publications

References 11 publications

In vivo efficacy of cefotaxime and amoxicillin against penicillin-susceptible, penicillin-resistant and penicillin-cephalosporin-resistant strains of Streptococcus pneumoniae in a mouse pneumonia model

In vivo efficacy of cefotaxime and amoxicillin against penicillin-susceptible, penicillin-resistant and penicillin-cephalosporin-resistant strains of Streptococcus pneumoniae in a mouse pneumonia model

High rate of erythromycin and clarithromycin resistance among Streptococcus pneumoniae isolates from blood cultures from Providence, R.I

Killing activity of cefpirome against penicillin-resistant Streptococcus pneumoniae isolates from patients with meningitis in a pharmacodynamic model simulating the cerebrospinal fluid concentration profile

Contact Info

Product

Resources

About